These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 25646113)

  • 21. An improved approach to measuring drug innovation finds steady rates of first-in-class pharmaceuticals, 1987-2011.
    Lanthier M; Miller KL; Nardinelli C; Woodcock J
    Health Aff (Millwood); 2013 Aug; 32(8):1433-9. PubMed ID: 23918488
    [TBL] [Abstract][Full Text] [Related]  

  • 22. New drug development in the United States from 1963 to 1999.
    Dimasi JA
    Clin Pharmacol Ther; 2001 May; 69(5):286-96. PubMed ID: 11371996
    [No Abstract]   [Full Text] [Related]  

  • 23. Are the economics of pharmaceutical research and development changing?: productivity, patents and political pressures.
    Grabowski H
    Pharmacoeconomics; 2004; 22(2 Suppl 2):15-24. PubMed ID: 15660474
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Future supply chains enabled by continuous processing--opportunities and challenges. May 20-21, 2014 Continuous Manufacturing Symposium.
    Srai JS; Badman C; Krumme M; Futran M; Johnston C
    J Pharm Sci; 2015 Mar; 104(3):840-9. PubMed ID: 25631279
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Biopharmaceutical industry's commitment to innovation and to the future of health care].
    Marini G
    Recenti Prog Med; 2006 Nov; 97(11):626-33. PubMed ID: 17252719
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Future European health care: cost containment, health care reform and scientific progress in drug research.
    Emilien G
    Int J Health Plann Manage; 1997; 12(2):81-101. PubMed ID: 10173136
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Potential of Continuous Manufacturing for Liposomal Drug Products.
    Worsham RD; Thomas V; Farid SS
    Biotechnol J; 2019 Feb; 14(2):e1700740. PubMed ID: 29781114
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Strategic funding priorities in the pharmaceutical sciences allied to Quality by Design (QbD) and Process Analytical Technology (PAT).
    Aksu B; De Beer T; Folestad S; Ketolainen J; Lindén H; Lopes JA; de Matas M; Oostra W; Rantanen J; Weimer M
    Eur J Pharm Sci; 2012 Sep; 47(2):402-5. PubMed ID: 22749874
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The economics of follow-on drug research and development: trends in entry rates and the timing of development.
    DiMasi JA; Paquette C
    Pharmacoeconomics; 2004; 22(2 Suppl 2):1-14. PubMed ID: 15660473
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The strategic relevance of manufacturing technology: An overall quality concept to promote innovation preventing drug shortage.
    Panzitta M; Ponti M; Bruno G; Cois G; D'Arpino A; Minghetti P; Mendicino FR; Perioli L; Ricci M
    Int J Pharm; 2017 Jan; 516(1-2):144-157. PubMed ID: 27838294
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Non-clinical Post-Marketing Commitments for newly licenced pharmaceuticals.
    Reeve LM
    Regul Toxicol Pharmacol; 2009 Nov; 55(2):181-7. PubMed ID: 19589365
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Changing innovation into a registered product: From concept to regulatory approval.
    Rhodes L
    Theriogenology; 2018 May; 112():75-81. PubMed ID: 28716338
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Biopharmaceutical benchmarks--2003.
    Walsh G
    Nat Biotechnol; 2003 Aug; 21(8):865-70. PubMed ID: 12894198
    [No Abstract]   [Full Text] [Related]  

  • 34. The role of the pharmaceutical industry in drug development and approval.
    Beleau MH
    Vet Hum Toxicol; 1998; 40 Suppl 2():17-9. PubMed ID: 9823577
    [No Abstract]   [Full Text] [Related]  

  • 35. Biotechnology partnerships--medicine for an ailing industry?
    DeLamarter J
    Nat Biotechnol; 2003 Aug; 21(8):847-8. PubMed ID: 12894192
    [No Abstract]   [Full Text] [Related]  

  • 36. Developing a paradigm of drug innovation: an evaluation algorithm.
    Caprino L; Russo P
    Drug Discov Today; 2006 Nov; 11(21-22):999-1006. PubMed ID: 17055409
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Lessons from Eprex for biogeneric firms.
    Louët S
    Nat Biotechnol; 2003 Sep; 21(9):956-7. PubMed ID: 12949539
    [No Abstract]   [Full Text] [Related]  

  • 38. [Pediatric drug development: ICH harmonized tripartite guideline E11 within the United States of America, the European Union, and Japan].
    Pflieger M; Bertram D
    Arch Pediatr; 2014 Oct; 21(10):1129-38. PubMed ID: 25175054
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Development times, clinical testing, postmarket follow-up, and safety risks for the new drugs approved by the US food and drug administration: the class of 2008.
    Moore TJ; Furberg CD
    JAMA Intern Med; 2014 Jan; 174(1):90-5. PubMed ID: 24166236
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The evolving role of collaboration in biotechnology.
    Gower JM
    Nat Biotechnol; 1998 May; 16 Suppl():31-2. PubMed ID: 9591261
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.